Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent Hodgkin lymphoma

2016 ◽  
Vol 5 (3) ◽  
pp. 320-323 ◽  
Author(s):  
Engin Alagoz ◽  
Semra Ince ◽  
Kursat Okuyucu ◽  
Aslı Ayan ◽  
Huseyin San ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Complete Remission ◽  
Hodgkin Lymphoma ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

Revised staging system for malignant lymphoma based on the Lugano classification

2019 ◽  
Vol 49 (10) ◽  
pp. 895-900 ◽  
Author(s):  
Wataru Munakata ◽  
Takashi Terauchi ◽  
Dai Maruyama ◽  
Hirokazu Nagai
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Hodgkin Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Bone Marrow Biopsies ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

Abstract The Lugano classification was published in 2014 to form the basis for revising the recommendations regarding anatomic staging and evaluation of disease before and after therapy. This staging system was adopted by the eighth edition of the Cancer Staging Manual of the American Joint Committee on Cancer. In this review, we aimed to discuss this updated staging system for malignant lymphomas. The most important change was that fluorodeoxyglucose positron emission tomography/computed tomography became the new standard imaging technique for staging of all fluorodeoxyglucose-avid histologies. Due to the introduction of fluorodeoxyglucose positron emission tomography/computed tomography for staging, the evaluation of not only lymph node involvement but also organ involvement, including liver or spleen, has become simplified. Furthermore, it is possible to eliminate bone marrow biopsies in patients with Hodgkin lymphoma and diffuse large B-cell lymphoma. Although patients were grouped according to the absence (A) or presence (B) of disease-related symptoms based on the previous classification, only the patients with Hodgkin lymphoma need to be assigned the designations A or B in this revision. Hopefully, these revised recommendations will improve patient management and the conduct of clinical trials.

Sign in / Sign up

Export Citation Format

Share Document